RBCC Visits Texas Genome-Mapping Target

  RBCC Visits Texas Genome-Mapping Target

Business Wire

NOKOMIS, Fla. -- January 22, 2013

Since the new year began, Rainbow Coral Corp. (OTCBB: RBCC) has wasted no time
in searching for new targets to add to its portfolio of projects for
commercialization. Last week, the Company’s executive leadership accepted an
invitation to tour a genome-mapping facility in Houston with which RBCC could
soon partner.

New healthcare innovations related to the human genome represent a target-rich
area of interest for RBCC.The Texas company currently being reviewed performs
tests to identify genetic markers in patients that can potentially boost or
nullify the effects of certain medications.

Such testing could dramatically change the way medications are prescribed,
potentially fostering a significant reduction in global health care costs.

“Knowing specifics about an individual’s genetic make-up can greatly assist a
patient’s doctor in determining correct doses of medications as well as ruling
out medications that could prove harmful,” said RBCC CEO Patrick Brown.
“Genome mapping opens up a host of new possibilities for doctors and patients
alike, and we’re very interested in the technology’s economic potential.”

As the company searches for its next partner, RBCC’s biotech subsidiary
Rainbow Biosciences remains close to a joint venture deal with Amarantus
Bioscience, makers of exciting new diagnostic tools and therapies for
neurological diseases such as Parkinson’s.

Amarantus recently announced highly promising results in new animal trials of
its forthcoming Parkinson’s therapeutic, known as MANF.

For more information on RBCC and its biotechnology targets, please

Rainbow BioSciences is dedicated to developing new medical and research
technology innovations to compete alongside companies such as Amgen Inc.
(NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC) and Abbott Laboratories

Follow us on Twitter atwww.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division ofRainbow Coral Corp.(OTCBB:RBCC). The
Company continually seeks out new partnerships with biotechnology developers
to deliver profitable new medical technologies and innovations. For more
information on our growth-oriented business initiatives, please visit our
website atwww.rainbowbiosciences.com. For investment information and
performance data on the Company, please

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information included
herein for events occurring after the date hereof.


Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
Press spacebar to pause and continue. Press esc to stop.